How many clinical trials are tracked for Cognitive Dysfunction?

21 trials are tracked, 1 with published results.

Cognitive Dysfunction Research

Cognitive Dysfunction: what the trials found

Renew NCP-5 demonstrated a mean reduction in the Vascular Dementia Assessment Scale Cognitive Subscale (vADAS-cog) from baseline to 24 weeks, with scores of -9.76 and -5.31.

SAGE-718 was evaluated for safety and physiological impact; 64% of participants showed at least one potentially clinically significant change in vital signs, while 12-16% showed changes in laboratory assessments, and 32% showed changes in ECG measurements.

For the clinician treating this condition

Renew NCP-5 is associated with a reduction in vADAS-cog scores over a 24-week period.
SAGE-718 has been studied for safety, showing significant rates of clinical changes in vitals and lab assessments.

AI synthesis of 0 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Cognitive Dysfunction: current evidence & treatments

Cognitive dysfunction is associated with various medical conditions and risk factors. Systemic lupus erythematosus (SLE) is linked to a 53% higher odds of cognitive impairment (OR 1.53) ⁶. In patients with atrial fibrillation, a history of hypertension increases the risk of cognitive impairment (OR 2.22) ⁷. Among coronary heart disease patients, the pooled prevalence of cognitive impairment is 36.6%, with age as a significant risk factor (OR 1.10) ²². Depression is associated with an increased risk of progression from mild cognitive impairment to Alzheimer's disease or dementia ¹⁴. Additionally, food insecurity in older adults is linked to poorer diet quality and higher obesity risk, which may contribute to cognitive decline ¹.

Several interventions show promise for improving cognitive function. Combined exercise and dietary supplementation modestly improves global cognition in mild cognitive impairment (SMD 0.15) ². Acupuncture alone significantly outperforms placebo (effect size 1.09) and Western medicine alone (effect size 0.45) for Alzheimer's disease and mild cognitive impairment ³. Transcranial direct current stimulation (tDCS) improves global cognition in Alzheimer's and MCI (SMD 0.49) ¹³, and combined exercise and tDCS also shows benefit (SMD 0.62) ²¹. Computerized cognitive training yields moderate improvement in overall cognitive function for MCI ¹⁸. Repetitive transcranial magnetic stimulation improves global cognition and executive function in MCI ¹⁶. Music therapy may improve cognition and neuropsychiatric symptoms ⁹, and combined virtual reality and music therapy alleviates cognitive impairment ⁵. Ashwagandha supplementation improves memory (SMD 0.52), attention (SMD 0.29), and executive function (SMD -0.42) ²⁰. Zingiberaceae-derived interventions (e.g., curcumin) improve memory-related outcomes (SMD 0.19) ¹⁹.

Biomarkers and diagnostic tools are being explored. Higher peripheral Galectin-3 levels are found in cognitive impairment (WMD 0.85) ¹¹. Retinal biomarkers (RNFL and GCL-IPL thickness) measured by OCT may differentiate frontotemporal dementia from Alzheimer's disease ¹⁰. AI-assisted PET radiomics achieves high accuracy (AUC 0.96) for distinguishing Alzheimer's from MCI, outperforming conventional amyloid-PET ¹⁷. Preclinical evidence suggests Atractylenolide III has neuroprotective effects in cognitive impairment models ⁸. Loneliness in younger men is associated with cognitive decline ⁴. PRKRA gene variants are enriched in tinnitus patients with MCI ¹⁵. Cognitive dysfunction is common after pediatric liver transplant (24% incidence) ²⁴, and ICU CogHab cognitive rehabilitation is being studied in ICU survivors ²⁵. Ferroptosis may play a role in postoperative cognitive dysfunction in older surgical patients ¹². Soil contaminants and micronutrient depletion are linked to neurodegenerative processes ²³.

SLE and hypertension are significant risk factors for cognitive impairment ⁶⁷.

Acupuncture, tDCS, and computerized cognitive training show efficacy for improving cognition in MCI and Alzheimer's ³¹³¹⁸.

Ashwagandha and Zingiberaceae-derived supplements improve memory and executive function ¹⁹²⁰.

AI-assisted PET radiomics outperforms conventional methods for Alzheimer's diagnosis ¹⁷.

Cognitive impairment prevalence is high in coronary heart disease (36.6%) and after pediatric liver transplant (24%) ²²²⁴.

AI-generated synthesis of 25 cited studies, updated Jun 12, 2026. How we use AI.

‹ Prev 1 2 3 4 5 … 8 Next ›

Questions about Cognitive Dysfunction

How common is cognitive dysfunction in children who have had a liver transplant?

About 24% of children who have a liver transplant experience cognitive dysfunction, with higher rates in those transplanted before age 1 (39.4%) and in Asia (30.6%).

Full answer →

Cognitive Dysfunction

Subtypes of Cognitive Dysfunction

Clinical Trials for Cognitive Dysfunction

Cognitive Dysfunction: what the trials found

Recent results — preliminary, needs further review

For the clinician treating this condition

Cognitive Dysfunction: current evidence & treatments

Key drugs in the evidence

Latest findings

Questions about Cognitive Dysfunction